Zymeworks Inc (ZYME)

$13.88 -0.11 (-0.79%)
Market Cap 963.60M
Revenue (ttm) 76.01M
Net Income (ttm) -118.67M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -156.12%
Debt to Equity Ratio 0.00
Volume 323,700
Avg Vol 512,504
Day's Range N/A - N/A
Shares Out 68.88M
Stochastic %K 44%
Beta 1.10
Analysts Strong Sell
Price Target $20.44

Latest News on ZYME

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

Jan 8, 2025, 4:05 PM EST - 9 days ago

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule

Dec 19, 2024, 9:00 AM EST - 4 weeks ago

Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule

Zymeworks Announces Participation in Upcoming Investor Conferences

Nov 21, 2024, 6:05 AM EST - 2 months ago

Zymeworks Announces Participation in Upcoming Investor Conferences

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Nov 21, 2024, 6:00 AM EST - 2 months ago

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors

Nov 5, 2024, 6:00 AM EST - 2 months ago

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors

Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab

Nov 4, 2024, 4:28 AM EST - 2 months ago

Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab

Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 10:05 PM EDT - 2 months ago

Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

Oct 25, 2024, 6:00 AM EDT - 3 months ago

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers

Oct 21, 2024, 6:00 AM EDT - 3 months ago

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers

Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024

Oct 10, 2024, 6:30 AM EDT - 3 months ago

Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024

Zymeworks Approaching A Moment Of Truth With Zanidatamab

Sep 27, 2024, 2:47 PM EDT - 4 months ago

Zymeworks Approaching A Moment Of Truth With Zanidatamab

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

Sep 18, 2024, 6:00 AM EDT - 4 months ago

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

Sep 3, 2024, 4:30 PM EDT - 4 months ago

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

Zymeworks Inc. (ZYME) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 10:58 PM EDT - 6 months ago

Zymeworks Inc. (ZYME) Q2 2024 Earnings Call Transcript

Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock

Aug 1, 2024, 4:10 PM EDT - 6 months ago

Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock

Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer

Jul 25, 2024, 4:30 PM EDT - 6 months ago

Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate

Jul 22, 2024, 6:00 AM EDT - 6 months ago

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate

Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024

Jul 11, 2024, 6:30 AM EDT - 6 months ago

Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers

Jun 17, 2024, 6:00 AM EDT - 7 months ago

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers

Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer

Jun 10, 2024, 6:00 AM EDT - 7 months ago

Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer

Zymeworks Inc. (ZYME) Q1 2024 Earnings Call Transcript

May 2, 2024, 8:04 PM EDT - 9 months ago

Zymeworks Inc. (ZYME) Q1 2024 Earnings Call Transcript

Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data

Apr 18, 2024, 3:06 PM EDT - 9 months ago

Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data

Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

Apr 11, 2024, 6:00 AM EDT - 10 months ago

Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting

Apr 8, 2024, 6:00 AM EDT - 10 months ago

Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting

Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors

Mar 28, 2024, 6:00 AM EDT - 10 months ago

Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors

Zymeworks Inc. (ZYME) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 11:17 PM EST - 11 months ago

Zymeworks Inc. (ZYME) Q4 2023 Earnings Call Transcript

Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 6, 2024, 4:09 PM EST - 11 months ago

Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting

Mar 5, 2024, 4:30 PM EST - 11 months ago

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting

Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments

Mar 5, 2024, 12:16 AM EST - 11 months ago

Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments